786 related articles for article (PubMed ID: 36195876)
21. Prognostic prediction using a gene signature developed based on exhausted T cells for liver cancer patients.
Zhou Y; Wu W; Cai W; Zhang D; Zhang W; Luo Y; Cai F; Shi Z
Heliyon; 2024 Mar; 10(6):e28156. PubMed ID: 38533068
[TBL] [Abstract][Full Text] [Related]
22. Identification and Validation of Cuproptosis-Related Prognostic Signature and Associated Regulatory Axis in Uterine Corpus Endometrial Carcinoma.
Chen Y
Front Genet; 2022; 13():912037. PubMed ID: 35937995
[No Abstract] [Full Text] [Related]
23. Identification of a cuproptosis and copper metabolism gene-related lncRNAs prognostic signature associated with clinical and immunological characteristics of hepatocellular carcinoma.
Yuan W; Xiao JH; Zhang JS; Mao BL; Wang PZ; Wang BL
Front Oncol; 2023; 13():1153353. PubMed ID: 37056336
[TBL] [Abstract][Full Text] [Related]
24. Identification of hepatocellular carcinoma-related subtypes and development of a prognostic model: a study based on ferritinophagy-related genes.
Wang G; Li J; Zhu L; Zhou Z; Ma Z; Zhang H; Yang Y; Niu Q; Wang X
Discov Oncol; 2023 Aug; 14(1):147. PubMed ID: 37555866
[TBL] [Abstract][Full Text] [Related]
25. Cuproptosis-related genes score: A predictor for hepatocellular carcinoma prognosis, immunotherapy efficacy, and metabolic reprogramming.
Nie G; Peng D; Wen N; Wang Y; Lu J; Li B
Front Oncol; 2023; 13():1096351. PubMed ID: 36845733
[TBL] [Abstract][Full Text] [Related]
26. Identification of the cuproptosis-related molecular subtypes and an immunotherapy prognostic model in hepatocellular carcinoma.
Zhang L; Xu J; Chu X; Zhang H; Yao X; Zhang J; Guo Y
BMC Bioinformatics; 2022 Nov; 23(1):485. PubMed ID: 36384423
[TBL] [Abstract][Full Text] [Related]
27. Cuproptosis-Related Genes MTF1 and LIPT1 as Novel Prognostic Biomarker in Acute Myeloid Leukemia.
Li Y; Kan X
Biochem Genet; 2024 Apr; 62(2):1136-1159. PubMed ID: 37561332
[TBL] [Abstract][Full Text] [Related]
28. Cuproptosis-Related LncRNA Signature for Predicting Prognosis of Hepatocellular Carcinoma: A Comprehensive Analysis.
Chen Q; Sun T; Wang G; Zhang M; Zhu Y; Shi X; Ding Z
Dis Markers; 2022; 2022():3265212. PubMed ID: 36452343
[TBL] [Abstract][Full Text] [Related]
29. Prognostic and immune microenvironment analysis of cuproptosis-related LncRNAs in breast cancer.
Pan Y; Zhang Q; Zhang H; Kong F
Funct Integr Genomics; 2023 Jan; 23(1):38. PubMed ID: 36640225
[TBL] [Abstract][Full Text] [Related]
30. In Silico Identification and Validation of Cuproptosis-Related LncRNA Signature as a Novel Prognostic Model and Immune Function Analysis in Colon Adenocarcinoma.
Wang Y; Huang X; Chen S; Jiang H; Rao H; Lu L; Wen F; Pei J
Curr Oncol; 2022 Sep; 29(9):6573-6593. PubMed ID: 36135086
[TBL] [Abstract][Full Text] [Related]
31. Identification of cuproptosis-related subtypes and development of a prognostic signature in colorectal cancer.
Huang Y; Yin D; Wu L
Sci Rep; 2022 Oct; 12(1):17348. PubMed ID: 36253436
[TBL] [Abstract][Full Text] [Related]
32. Database Mining Detected a Cuproptosis-Related Prognostic Signature and a Related Regulatory Axis in Breast Cancer.
Jiang B; Zhu H; Feng W; Wan Z; Qi X; He R; Xie L; Li Y
Dis Markers; 2022; 2022():9004830. PubMed ID: 36312586
[TBL] [Abstract][Full Text] [Related]
33. A Novel Cuproptosis-Associated Gene Signature to Predict Prognosis in Patients with Pancreatic Cancer.
Du Y; Jiang W; Hou S; Chen Z; Zhou W
Biomed Res Int; 2023; 2023():3419401. PubMed ID: 36714025
[TBL] [Abstract][Full Text] [Related]
34. Construction of prognostic risk model of bladder cancer based on cuproptosis-related long non-coding RNAs.
Xu C; Chen A; Mao C; Cui B
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 52(2):139-147. PubMed ID: 37283097
[TBL] [Abstract][Full Text] [Related]
35. Development and experimental verification of a prognosis model for cuproptosis-related subtypes in HCC.
Wang Y; Zhang Y; Wang L; Zhang N; Xu W; Zhou J; Zhao Y; Zhu W; Zhang T; Wang L
Hepatol Int; 2022 Dec; 16(6):1435-1447. PubMed ID: 36065073
[TBL] [Abstract][Full Text] [Related]
36. Targeting PRKDC activates the efficacy of antitumor immunity while sensitizing to chemotherapy and targeted therapy in liver hepatocellular carcinoma.
Pan Y; Zhu Q; Hong T; Cheng J; Tang X
Aging (Albany NY); 2024 May; 16(10):9047-9071. PubMed ID: 38787389
[TBL] [Abstract][Full Text] [Related]
37. Expression Profiles of Cuproptosis-Related Genes Determine Distinct Subtypes of Pancreatic Ductal Adenocarcinoma.
Chen Y; Zou X; Ma M; Liu Y; Wang R; Dai Z; Tashiheng Y; Yan Y; Yu X; Wang X; Liu C; Lin X; Cheng H
Curr Oncol; 2023 Jan; 30(2):1648-1662. PubMed ID: 36826087
[TBL] [Abstract][Full Text] [Related]
38. Construction and validation of a novel cuproptosis-mitochondrion prognostic model related with tumor immunity in osteosarcoma.
Feng J; Wang J; Xu Y; Lu F; Zhang J; Han X; Zhang C; Wang G
PLoS One; 2023; 18(7):e0288180. PubMed ID: 37405988
[TBL] [Abstract][Full Text] [Related]
39. A signature based on neutrophil extracellular trap-related genes for the assessment of prognosis, immunoinfiltration, mutation and therapeutic response in hepatocellular carcinoma.
Wang L; Wang Q; Li Y; Qi X; Fan X
J Gene Med; 2024 Jan; 26(1):e3588. PubMed ID: 37715643
[TBL] [Abstract][Full Text] [Related]
40. Identification of a Necroptosis-Related Prognostic Signature and Associated Regulatory Axis in Liver Hepatocellular Carcinoma.
He A; Huang Z; Wang J; Lu H; Zhang R; Wu L; Feng Q
Dis Markers; 2022; 2022():3968303. PubMed ID: 35855852
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
